IL257929A - שיטות לטיפול במיאלומה נפוצה ולוקמיה תאי פלסמה באמצעות תרפיה של תאי t - Google Patents

שיטות לטיפול במיאלומה נפוצה ולוקמיה תאי פלסמה באמצעות תרפיה של תאי t

Info

Publication number
IL257929A
IL257929A IL257929A IL25792918A IL257929A IL 257929 A IL257929 A IL 257929A IL 257929 A IL257929 A IL 257929A IL 25792918 A IL25792918 A IL 25792918A IL 257929 A IL257929 A IL 257929A
Authority
IL
Israel
Prior art keywords
methods
multiple myeloma
treating multiple
cell therapy
cell leukemia
Prior art date
Application number
IL257929A
Other languages
English (en)
Other versions
IL257929B2 (he
IL257929B1 (he
Inventor
Guenther Koehne
Original Assignee
Memorial Sloan Kettering Cancer Center
Guenther Koehne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center, Guenther Koehne filed Critical Memorial Sloan Kettering Cancer Center
Publication of IL257929A publication Critical patent/IL257929A/he
Publication of IL257929B1 publication Critical patent/IL257929B1/he
Publication of IL257929B2 publication Critical patent/IL257929B2/he

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4242Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243Wilms tumor 1 [WT1]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL257929A 2015-09-10 2016-09-09 שיטות לטיפול במיאלומה נפוצה ולוקמיה תאי פלסמה באמצעות תרפיה של תאי t IL257929B2 (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562216525P 2015-09-10 2015-09-10
US201562220641P 2015-09-18 2015-09-18
PCT/US2016/050857 WO2017044678A1 (en) 2015-09-10 2016-09-09 Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy

Publications (3)

Publication Number Publication Date
IL257929A true IL257929A (he) 2018-05-31
IL257929B1 IL257929B1 (he) 2024-02-01
IL257929B2 IL257929B2 (he) 2024-06-01

Family

ID=57068181

Family Applications (1)

Application Number Title Priority Date Filing Date
IL257929A IL257929B2 (he) 2015-09-10 2016-09-09 שיטות לטיפול במיאלומה נפוצה ולוקמיה תאי פלסמה באמצעות תרפיה של תאי t

Country Status (14)

Country Link
US (1) US20190381098A1 (he)
EP (1) EP3347028A1 (he)
JP (1) JP6947720B2 (he)
KR (1) KR20180048992A (he)
CN (1) CN108348552A (he)
AU (1) AU2016320877A1 (he)
CA (1) CA2997757A1 (he)
HK (1) HK1257882A1 (he)
IL (1) IL257929B2 (he)
MX (1) MX395106B (he)
RU (1) RU2743381C2 (he)
TW (1) TWI759270B (he)
WO (1) WO2017044678A1 (he)
ZA (1) ZA201801656B (he)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018217203A1 (en) 2017-05-25 2018-11-29 Oreilly Richard John Use of the il-15/il-15ra complex in the generation of antigen-specific t cells for adoptive immunotherapy
AU2018355145A1 (en) 2017-10-23 2020-04-30 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy
EP3765602A1 (en) 2018-03-14 2021-01-20 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line for adoptive cellular therapy
CN111643525A (zh) * 2020-06-16 2020-09-11 济宁医学院 引发免疫排斥反应在肿瘤治疗中的应用及其方法
CN113881632B (zh) * 2021-09-29 2023-09-29 四川省医学科学院·四川省人民医院 一种提高dc细胞活性的细胞培养基及培养方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1038929B (zh) * 1998-07-31 2005-05-06 株式会社国际癌症免疫研究所 基於癌抑制基因wt1的产物的癌抗原
PL201881B1 (pl) * 1998-09-30 2009-05-29 Corixa Corp Izolowany polipeptyd składający się z immunogennej części natywnego WT1, zawierająca go kompozycja farmaceutyczna i szczepionka oraz polinukleotyd kodujący ten polipeptyd
US20080070835A1 (en) * 2003-11-05 2008-03-20 International Institute Of Cancer Immunology, Inc Hla-Dr-Binding Antigen Peptide Derived From Wt1
FR2931163B1 (fr) * 2008-05-16 2013-01-18 Ets Francais Du Sang Lignee de cellules dendritiques plasmacytoides utilisee en therapie cellulaire active ou adoptive
RU2506311C2 (ru) * 2008-10-30 2014-02-10 Йеда Рисёрч Энд Девелопмент Ко. Лтд. Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний
CA2861206C (en) * 2012-01-13 2021-07-06 Richard J. O'reilly Immunogenic wt-1 peptides and methods of use thereof

Also Published As

Publication number Publication date
US20190381098A1 (en) 2019-12-19
MX2018002816A (es) 2018-06-08
IL257929B2 (he) 2024-06-01
EP3347028A1 (en) 2018-07-18
MX395106B (es) 2025-03-21
TWI759270B (zh) 2022-04-01
CN108348552A (zh) 2018-07-31
IL257929B1 (he) 2024-02-01
AU2016320877A1 (en) 2018-04-19
RU2018112526A (ru) 2019-10-10
JP6947720B2 (ja) 2021-10-13
TW201714619A (zh) 2017-05-01
JP2018530534A (ja) 2018-10-18
RU2018112526A3 (he) 2020-01-31
CA2997757A1 (en) 2017-03-16
RU2743381C2 (ru) 2021-02-17
HK1257882A1 (zh) 2019-11-01
WO2017044678A1 (en) 2017-03-16
KR20180048992A (ko) 2018-05-10
ZA201801656B (en) 2022-12-21

Similar Documents

Publication Publication Date Title
GB2573664B (en) Viral methods of T cell therapy
ZA201804227B (en) Methods of treating cancer
IL255189A0 (he) שיטות לטיפול בסרטן
IL253795A0 (he) שיטות לטיפול בסרטן באמצעות תאי t משופעלים
GB2592821B (en) Modified cells and methods of therapy
ZA201708567B (en) Methods of treating epithelioid cell tumors
IL259992A (he) שיטה לטיפול ברגישות מוגברת לכאב
ZA201706059B (en) Method of treatment with tradipitant
EP3319619A4 (en) Methods of treating colitis
ZA201807431B (en) Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells
IL256207B (he) שיטות לטיפול בטרשת נפוצה
SG11201706693QA (en) Methods of treating infertility
ZA201801656B (en) Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy
IL253847A0 (he) שיטות לטיפול במחלות
EP3491129A4 (en) METHODS OF TREATING OSMIDROSIS
EP3281243A4 (en) Method of treating carbon electrode
IL267231A (he) שיטות לטיפול במחלות קשורות לתאי ilc2
IL262951A (he) שיטות לטיפול בתרופות קשורות לתאי ilc3
GB201512139D0 (en) Methods of treatment
HK40035157A (en) Methods of treating high risk multiple myeloma
PT3265075T (pt) Terapêutica de associação com roneparstat para o mieloma múltiplo
HK1262625A1 (en) Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells
PT3261661T (pt) Menotropina para tratar a infertilidade
GB201512334D0 (en) Methods for selective killing of cancer cells
AU2015905220A0 (en) Methods of treatment